Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / VBLT - VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment

VBLT - VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment

Vascular Biogenics Ltd.
  • VBL Therapeutics recently announced that they were allowed to add progression-free survival as a second primary endpoint for VB-111's Phase III OVAL study in ovarian cancer.
  • The addition of the PFS endpoint could reduce VB-111's regulatory timeline by one year. Thus, moving VBL closer to commercialization.
  • I reveal my plans for managing my VBLT position.

For further details see:

VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment
Stock Information
Company Name: Vascular Biogenics Ltd.
Stock Symbol: VBLT
Market: NASDAQ
Menu
VBLT VBLT Quote VBLT Short VBLT News VBLT Articles VBLT Message Board
Get VBLT Alerts

News, Short Squeeze, Breakout and More Instantly...